Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Lymphoma, Large B-Cell, Diffuse 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Rectal Neoplasms 1Pheochromocytoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Paraganglioma, Extra-Adrenal 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Osteosarcoma 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Gynecological Cancer 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Esophageal Squamous Cell Carcinoma 1Digestive System Diseases 1Carcinoma 1Breast Neoplasms 1Breast Neoplasm Female 1

Interventions

pertuzumab 1penpulimab 1dalpiciclib 1anlotinib 1Tretinoin 1Trastuzumab 1Fulvestrant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasm Female × penpulimab × Clear all
NCT05244993 2022-07-12

AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer

Liaoning Cancer Hospital & Institute

Phase 2 Unknown
42 enrolled
Breast

Breast Neoplasm Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡